Automated Interpretation of Clinical Electroencephalograms Using Artificial Intelligence

Jesper Tveit, PhD; Harald Aurlien, MD, PhD; Sergey Plis, PhD; Vince D. Calhoun, PhD; William O. Tatum, DO; Donald L. Schomer, MD; Aatf M. Husain, MD; Sudha Kessler, MD; Firas Fahoum, MD; William B. Gallentine, DO; Elena Gardella, MD, PhD; Cecil D. Hahn, MD; Aatif M. Husain, MD; Sudha Kessler, MD; Mustafa Aykut Kural, MD; Fábio A. Nascimento, MD; Hatie Tankisi, MD, PhD; Line B. Ulvin, MD; Richard Wennberg, MD, PhD; Sándor Beniczky, MD, PhD

**IMPORTANCE** Electroencephalograms (EEGs) are a fundamental evaluation in neurology but require special expertise unavailable in many regions of the world. Artificial intelligence (AI) has a potential for addressing these unmet needs. Previous AI models address only limited aspects of EEG interpretation such as distinguishing abnormal from normal or identifying epileptiform activity. A comprehensive, fully automated interpretation of routine EEG based on AI suitable for clinical practice is needed.

**OBJECTIVE** To develop and validate an AI model (Standardized Computer-based Organized Reporting of EEG–Artificial Intelligence [SCORE-AI]) with the ability to distinguish abnormal from normal EEG recordings and to classify abnormal EEG recordings into categories relevant for clinical decision-making: epileptiform-focal, epileptiform-generalized, nonepileptiform-focal, and nonepileptiform-diffuse.

**DESIGN, SETTING, AND PARTICIPANTS** In this multicenter diagnostic accuracy study, a convolutional neural network model, SCORE-AI, was developed and validated using EEGs recorded between 2014 and 2020. Data were analyzed from January 17, 2022, until November 14, 2022. A total of 30,493 recordings of patients referred for EEG were included into the development data set annotated by 17 experts. Patients aged more than 3 months and not critically ill were eligible. The SCORE-AI was validated using 3 independent test data sets: a multicenter data set of 100 representative EEGs evaluated by 11 experts, a single-center data set of 9785 EEGs evaluated by 14 experts, and for benchmarking with previously published AI models, a data set of 60 EEGs with external reference standard. No patients who met eligibility criteria were excluded.

**MAIN OUTCOMES AND MEASURES** Diagnostic accuracy, sensitivity, and specificity compared with the experts and the external reference standard of patients’ habitual clinical episodes obtained during video-EEG recording.

**RESULTS** The characteristics of the EEG data sets include development data set (N = 30,493; 14,980 men; median age, 25.3 years [95% CI, 1.3-76.2 years]), multicenter test data set (N = 100; 61 men, median age, 25.8 years [95% CI, 4.1-85.5 years]), single-center test data set (N = 9785; 5168 men; median age, 35.4 years [95% CI, 0.6-87.4 years]), and test data set with external reference standard (N = 60; 27 men; median age, 36 years [95% CI, 3-75 years]). The SCORE-AI achieved high accuracy, with an area under the receiver operating characteristic curve between 0.89 and 0.96 for the different categories of EEG abnormalities, and performance similar to human experts. Benchmarking against 3 previously published AI models was limited to comparing detection of epileptiform abnormalities. The accuracy of SCORE-AI (88.3%; 95% CI, 79.2%-94.9%) was significantly higher than the 3 previously published models (P < .001) and similar to human experts.

**CONCLUSIONS AND RELEVANCE** In this study, SCORE-AI achieved human expert level performance in fully automated interpretation of routine EEGs. Application of SCORE-AI may improve diagnosis and patient care in underserved areas and improve efficiency and consistency in specialized epilepsy centers.

JAMA Neurol. doi:10.1001/jamaneurol.2023.1645
Published online June 20, 2023.

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Sándor Beniczky, MD, PhD, Aarhus University and Danish Epilepsy Centre, Visby Allé 5, 4293 Danaland, Denmark (sbz@filadelfia.dk).
Epileptiform and nonepileptiform EEGs are among the most common findings in clinical EEGs.

**Key Points**

**Question** Can an artificial intelligence (AI) model be trained to interpret routine clinical electroencephalograms (EEGs) with accuracy equivalent to that of human experts?

**Findings** In this diagnostic study, an AI model (SCORE-AI) was trained on 30,493 EEGs to separate normal from abnormal recordings then classify abnormal recordings as epileptiform-focal, epileptiform-generalized, nonepileptiform-focal, or nonepileptiform-diffuse. The SCORE-AI was validated using 3 independent test data sets consisting of 9,045 EEGs not used for training; SCORE-AI achieved diagnostic accuracy similar to human experts.

**Meaning** Results of this study suggest that application of SCORE-AI may have utility in improving patient care in underserved areas and efficiency and consistency in specialized centers.

**Methods**

We report the study using the Standards for Reporting of Diagnostic Accuracy (STARD) reporting guideline. As the reporting guideline for AI-Centered Diagnostic Accuracy Studies (STARD-AI) is still under development, we included the AI-specific aspects according to the Standard Protocol Items: Recommendations for Interventional Trials-Artificial Intelligence (SPIRIT-AI) extension.

**Development of the AI Model**

The data set used for development consisted of 30,493 anonymized EEG recordings collected from Haukeland University Hospital, Bergen, Norway, and the Danish Epilepsy Center, Dianalund, Denmark, using NicoletOne equipment (Natus Neuro). A holdout test data set consisting of 2549 EEGs was set aside and not used for development (eFigure 1 and eTable 1 in Supplement 1).
The mean EEG duration was 33 minutes (95% CI, 20-77 minutes). All EEGs had human expert assessments (a total of 17 physicians), using SCORE terminology implemented in the SCORE EEG Premium software (Holberg EEG). EEG signals from the 19 sensors (10-20 system) and ECG were extracted. The study was approved by the institutional review board and data safety officer at the Danish Epilepsy Centre. As the study used anonymized data sets of previously recorded EEGs, patient consent was not needed.

The SCORE-AI was developed in Python using TensorFlow (eAppendix 1 in Supplement 1) using EEGs recorded between 2014 and 2020. Data were analyzed from January 17, 2022, until November 14, 2022. All the input EEGs and ECG signals were converted into NumPy arrays. The model was configured to access 19 channels of EEG signals, 1 channel of ECG signal as well as the patient age and sex as input. A fixed Fourier resampling was applied to the input data. The final AI model (SCORE-AI) used input frequencies between 0.5 and 128 Hz with a sampling rate of 256 Hz.

The SCORE-AI model was configured to give 5 output scalars, 0<xi<1, where x0 is the normality predictor and xi,0<4 predicts one of the abnormal categories: epileptiform-focal (x1), epileptiform-generalized (x2), nonepileptiform-diffuse (x3), and nonepileptiform-focal (x4). The values x1 to x4 were mutually independent, but a constraint was placed such that 1 = x0 > max (x1, x2, x3, x4).

The model architecture was determined in the main development phase (eFigure 1 in Supplement 1). No automatic optimization of hyperparameters was performed. The results on the cross-validation data sets are shown in eFigure 2 in Supplement 1. The resulting neural networks are shown in eFigure 7 in Supplement 1.

Once the final model architecture was chosen, the model was retrained on the entire development data set (eFigure 3 in Supplement 1). The development data set was then used to determine the model output threshold (eTable 2 in Supplement 1) yielding the best accuracy estimate and to produce calibration curves (eFigure 4 in Supplement 1), enabling probabilistic interpretation of the model output.

The model was converted into a C++ plugin (dll interface) for the Windows platform. Similar interfaces can be set up for Linux or Mac computers. The output of the model is the assessment of the EEG recording as normal, one of the abnormal categories or a combination of the abnormal categories. The integration of SCORE-AI with the NeuroWorks EEG reader (Natus Neuro), autoSCORE, makes it possible to highlight the abnormal epochs within the EEG recording (eFigure 5 in Supplement 1) so that the expert can adjust the automated assessment, if needed. The SCORE-AI performs a fully automated analysis (ie, no human interaction is needed to obtain the output of the model).

Clinical Validation of the AI Model

The Test Data Sets

For clinical validation, we used independent test data sets consisting of EEGs recorded from patients who were not included in the development phase. We used a fixed and frozen model and threshold values. The index test was the model output. For an expected sensitivity of 75% and specificity of 90%, with a 10% error (±5%) when calculating sample size, we needed at least 85 EEGs.

Multicenter Test Data Set | To account for the variability in human expert assessment, 11 experts (raters) from 11 different centers, who participated in the development phase (eTable 5 in Supplement 1), independently evaluated a data set of 100 representative routine EEGs, recorded in different centers with different EEG equipment. The raters did not participate in assessing the EEGs in the development data set. The raters independently labeled each EEG using the same categories of EEG abnormalities as described above. The reference standard was majority consensus scoring of the raters.

Inclusion criteria included a targeted distribution of 60 normal recordings vs 40 abnormal recordings. From the holdout data set (eTable 1 in Supplement 1), 75 EEGs (48 adult and 27 pediatric) were randomly selected. The remaining 25 EEGs (17 adult, 8 pediatric) were selected from a data set of 150 anonymized EEGs from the Mayo Clinic. Exclusion criteria included patients aged 3 months or younger (neonatal EEGs) and recordings from intensive care units (ICUs) (EEGs with rhythmic and periodic patterns in critically ill patients were excluded). eTable 6 in Supplement 1 shows the distribution of the 100 patients in the multicenter test data set.

The raters independently evaluated the EEGs. The age and sex of the patient were disclosed for each EEG. The raters were blinded to all other data and to the output of the algorithm. The raters were free to change montages, filters, gain, and time resolution while reviewing EEGs.

Large Single-Center Test Data Set | We compared the output of SCORE-AI with the clinical assessments in a large SCORE EEG data set from Oslo University Hospital (Norway) consisting of 9785 EEGs (5168 male; median age: 38.9 years; 95% CI, 0.6-87.4 years). This center did not participate in the development of the model. Fourteen different physicians assessed the EEGs in this data set, but each EEG was assessed by a single physician in clinical practice. Neonatal and ICU recordings were also excluded from this data set. Mean duration of the recordings was 31 minutes (95% CI, 15-54 minutes). EEGs were recorded with NicoletOne equipment and described using the SCORE EEG Premium software. In this data set 4681 EEG results (47.83%) were abnormal.

Outcome Measures

In the multicenter multirater test data set, we determined the interrater agreement among the 11 human experts, and between SCORE-AI and the human experts (eFigure 6 in Supplement 1). Using majority consensus as reference standard in the multicenter test data set, we determined the diagnostic accuracy measures of SCORE-AI (sensitivity, specificity, accuracy, positive and negative predictive values) using the conventional formulas.

In the large single-center test data set, we calculated the intertest agreement between SCORE-AI and the clinical assessment by the human experts. We hypothesized that the agreement would be within range of the agreement between human experts.
Automated Interpretation of Clinical Electroencephalograms Using Artificial Intelligence

Comparison With Other Approaches

Multicenter Test Data Set

To our knowledge, there are no other commercially available or open-source AI models for comprehensive, fully automated assessment of routine clinical EEGs. We used the spike-detection approach of encevis (Austrian Institute of Technology), software approved by the US Food and Drug Administration and certified in the European Union by Conformité Européen, to compare this specific aspect with the performance of SCORE-AI in the multicenter test data set. For this purpose, the categories epileptiform-focal and epileptiform-generalized were combined, and we compared the accuracy of the 2 approaches for identifying recordings containing epileptiform abnormalities in the multicenter test data set.

Benchmarking With Previously Published AI Models

To compare the performance of SCORE-AI with 3 previously published models (encevis, SpikeNet, Persyst), we used the EEG data set from a previous study. The median age in this data set was 36 years (95% CI, 3-77 years). This data set consisted of 20-minute routine clinical EEGs containing sharp transients (epileptiform or not) from 60 patients: 30 with epilepsy (with 340 interictal epileptiform discharges in total) and 30 with nonepileptic paroxysmal events. This data set had an external independent reference standard at the recording level (ie, epilepsy vs nonepilepsy), derived from video-EEG recordings of patients obtained during their habitual clinical episodes. As the previously published models were spike detectors, we had to limit the evaluation to the accuracy of detecting epileptiform discharges. We then compared sensitivity, specificity, and overall accuracy.

Statistical Analysis

Gwet ACI agreement coefficients were used for measuring interrater agreement, and the strength of agreement beyond chance was interpreted according to Landis and Koch criteria. For computation of the 95% CIs, bootstrap resampling (n = 10 000 to 100 000) was used for all metrics except the Gwet ACI statistic. Bayesian bootstrap resampling with smoothing was used on the multirater multicenter data set of 100 EEGs as well as for the 60 EEGs with external reference standard (raw figures available in eTable 4 of Supplement 1). Otherwise, for the holdout test data set and the encevis comparison, plain bootstrap resampling was used. The smoothing was achieved by stochastically perturbing the confusion matrix by adding random noise from a uniform Dirichlet distribution in each bootstrap sample. For the ACI statistic we constructed the 95% CIs from the standard deviations as suggested in Gwet and Gwet. The Python packages SciPy, NumPy, and Pandas were used to compute the results. Inkscape and Pyplot were used to generate figures. Statistical significance was set at 2-sided \( P < .05 \). Intra-rater agreement comparisons were based on 95% CIs and considered statistically significant if there was no overlap.

Results

The characteristics of the EEG data sets include development data set (N = 30 493; 14 980 men; median age, 25.3 years [95% CI, 1.3-76.2 years]), multicenter test data set (N = 100; 61 men, median age, 25.8 years [95% CI, 4.1-85.5 years]), single-center test data set (N = 9785; 5168 men; median age, 35.4 years [95% CI, 0.6-87.4 years]), and test data set with external reference standard (N = 60; 27 men; median age, 36 years [95% CI, 3-75 years]). The performance in the holdout EEG data set (n = 2549) is shown in the Figure. The SCORE-AI achieved high accuracy, with an area under the receiver operating characteristic curve between 0.89 and 0.96 for the different categories of EEG abnormalities.

Table 1 shows the interrater agreement (measured as Gwet agreement coefficient [ACI]) among the 11 human experts and between SCORE-AI and the majority consensus in the multicenter data set (n = 100). There was almost perfect agreement (Gwet ACI = 0.9) among experts concerning the presence of generalized epileptiform discharges, and substantial agreement (Gwet ACI of 0.63-0.72) on focal epileptiform discharges, diffuse nonepileptiform abnormalities, and on recordings considered to be normal. The interrater agreement was moderate (Gwet ACI of 0.50-0.59) for the presence of focal nonepileptiform abnormalities, and for the exact match when several abnormalities were present in the same recording. Beyond-chance agreement between SCORE-AI and the majority consensus of human experts was similar to the agree-
ment among human experts for all aspects except for identifying normal EEG recordings (Gwet AC1 = 0.9) and multiple abnormalities (Gwet AC1 = 0.69) (Table 1), for which SCORE-AI had a significantly higher agreement with the majority consensus compared with the agreement among human experts (almost perfect vs substantial agreement). There was no significant difference in the overall diagnostic accuracy between experts and SCORE-AI in the multicenter data set (Table 2).

In the large external single-center test data set (n = 9785), agreement between SCORE-AI and clinical evaluation of the recordings was within the range of the human expert interrater variability for identifying normal recordings (0.74) and recordings with generalized epileptiform abnormalities (0.95), and significantly higher for the remaining categories (0.64-0.87) (Table 3). Since none of the currently available AI models provides a comprehensive fully automated assessment of routine clinical EEGs, we limited the benchmarking to the comparison of the ability to identify epileptiform discharges by combining focal and generalized categories (Table 4). In the multicenter test data set compared with encevis software,22 SCORE-AI had significantly higher specificity, positive predictive value, and accuracy, but lower sensitivity.

In the previously published data sets25 with external reference standard based on information obtained from epilepsy monitoring units, fully automated detection of epileptiform discharges using the 3 previously published AI models (encevis, SpikeNet, and Persyst) had specificity (3%-63%) too low for clinical implementation (eTable 7 in Supplement 1).25 SCORE-AI demonstrated substantially greater specificity compared with the previously published models (90% vs 3%-63%) and was more specific than the majority consensus of the 3 human experts (73.3%) (eTable 7 in Supplement 1). The sensitivity of SCORE-AI (86.7%) was similar to the sensitivity of the human experts (93.3%), higher than the sensitivity of SpikeNet (66.7%), and lower than encevis (96.7%) and Persyst (100%) (eTable 7 in Supplement 1). The overall accuracy

### Table 1. Gwet AC1 Agreement Coefficients for the 11 Human Experts, SCORE-AI, and the Human Expert Majority Consensus

<table>
<thead>
<tr>
<th>EEG recording category</th>
<th>Agreement among the human experts (95% CI)</th>
<th>Agreement between SCORE-AI and majority consensus of human experts (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>0.723 (0.649-0.796)</td>
<td>0.903 (0.820-0.987)</td>
</tr>
<tr>
<td>Epileptiform-focal</td>
<td>0.723 (0.643-0.803)</td>
<td>0.757 (0.634-0.880)</td>
</tr>
<tr>
<td>Epileptiform-generalized</td>
<td>0.901 (0.854-0.949)</td>
<td>0.928 (0.865-0.991)</td>
</tr>
<tr>
<td>Nonepileptiform-diffuse</td>
<td>0.610 (0.519-0.721)</td>
<td>0.738 (0.608-0.866)</td>
</tr>
<tr>
<td>Nonepileptiform-focal</td>
<td>0.587 (0.499-0.674)</td>
<td>0.775 (0.657-0.893)</td>
</tr>
<tr>
<td>Exact match/multiple abnormalities</td>
<td>0.497 (0.433-0.561)</td>
<td>0.689 (0.611-0.766)</td>
</tr>
</tbody>
</table>

### Table 2. Average Accuracy of SCORE-AI and of the Human Experts With Respect to the Human Expert Majority Consensus on 100 EEGs From the Multicenter Test Data Set

<table>
<thead>
<tr>
<th>EEG recording category</th>
<th>Average accuracy (95% CI)</th>
<th>Difference (P value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCORE-AI</td>
<td>Human experts</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>95.00 (89.61-97.88)</td>
<td>0.9</td>
</tr>
<tr>
<td>Epileptiform-focal</td>
<td>84.69 (76.73-90.54)</td>
<td>.12</td>
</tr>
<tr>
<td>Epileptiform-generalized</td>
<td>94.9 (89.41-97.83)</td>
<td>.34</td>
</tr>
<tr>
<td>Nonepileptiform-diffuse</td>
<td>84.69 (76.63-90.83)</td>
<td>.33</td>
</tr>
<tr>
<td>Nonepileptiform-focal</td>
<td>85.71 (77.86-91.41)</td>
<td>.47</td>
</tr>
<tr>
<td>Exact match/multiple abnormalities</td>
<td>65.31 (54.93-73.60)</td>
<td>0.33</td>
</tr>
</tbody>
</table>

### Table 3. Gwet AC1 Agreement Coefficients Between SCORE-AI and Clinical Assessment

<table>
<thead>
<tr>
<th>EEG recording category</th>
<th>Agreement between SCORE-AI and the clinical assessment of the EEGs (95% CI)</th>
<th>Difference between SCORE-AI–HE agreement and HE-HE agreement (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>0.737 (0.723 to 0.750)</td>
<td>0.014 (−0.061 to 0.089)</td>
</tr>
<tr>
<td>Epileptiform-focal</td>
<td>0.871 (0.862 to 0.879)</td>
<td>0.147 (0.067 to 0.228)</td>
</tr>
<tr>
<td>Epileptiform-generalized</td>
<td>0.948 (0.943 to 0.953)</td>
<td>0.0471 (−0.001 to 0.095)</td>
</tr>
<tr>
<td>Nonepileptiform-diffuse</td>
<td>0.737 (0.723 to 0.750)</td>
<td>0.106 (0.014 to 0.199)</td>
</tr>
<tr>
<td>Nonepileptiform-focal</td>
<td>0.768 (0.756 to 0.780)</td>
<td>0.181 (0.092 to 0.269)</td>
</tr>
<tr>
<td>Exact match/multiple abnormalities</td>
<td>0.637 (0.627 to 0.647)</td>
<td>0.140 (0.075 to 0.205)</td>
</tr>
</tbody>
</table>
of SCORE-AI (88.3%; 95% CI, 79.2%-94.9%) was similar to the human experts (83.3%; 95% CI, 73%-91.4%) and more accurate (P < .001) than the 3 previously published AI models (eTable 7 in Supplement 1).

Discussion

In this diagnostic accuracy study, we developed and validated the first AI model (SCORE-AI) to date capable of fully automated and comprehensive assessment of routine clinical EEGs. The SCORE-AI achieved human expert performance in automated interpretation of routine clinical EEGs. These results warrant clinical implementation with a potential to improve patient care in remote and underserved areas where EEG expertise is scarce or unavailable. In addition, SCORE-AI may help improve efficiency and reduce excessive workloads for experts in tertiary care centers who regularly interpret high volumes of EEG recordings.

We designed the development and validation of the model with special care to avoid typical errors and sources of bias and tailored the process to address specific aspects pertinent to interpretation of clinical EEGs. We used a large data set of 30,493 EEGs, from different centers, to train the AI model. The EEGs were highly annotated by 17 human experts, using a standardized software tool (SCORE-EEG). For the clinical validation, we used a “fixed and frozen” model and thresholds. To avoid overfitting, no iterations (ie, adjustments) of the AI model were allowed in the clinical validation phase. The test data set was independent from the development data set. To ensure generalizability, we aimed for a test data set with a representative distribution and a large consecutive test data set of nearly 10,000 EEGs. The human experts providing the reference standard in the validation phase of the study were different from those who participated in the development portion of the process. In the multicenter test data set, EEGs were recorded with different EEG equipment. The analysis process was fully automated and blinded to all other data.

The SCORE-AI is the first model to date capable of completing a fully automated and comprehensive clinically relevant assessment of routine EEGs. The output of SCORE-AI provides a more complex classification of EEG abnormalities than previously published AI models. Identifying the presence of epileptiform activity in the EEGs helps in diagnosing epilepsy. Distinguishing focal from generalized epileptiform discharges additionally aids in choosing optimal antiseizure medication. Distinguishing focal from diffuse nonepileptiform EEG abnormalities directs further diagnostic steps, such as neuroimaging for the former case and a search for systematic etiologies in the latter. Hence, the granularity of classifying abnormal EEGs provides sufficient information for the referring physician to make clinical decisions.

Another remarkable finding in our study is the interrater agreement among human experts. Previous studies found only fair to moderate agreement in EEG reading. However, those studies assessed short segments of EEG with selected abnormal patterns, and not a complete, continuous recording, as is the case in the clinical setting. In this study, we found better results with comprehensive expert assessment of the entire routine EEG recording; almost perfect agreement for generalized epileptiform abnormalities, substantial agreement for focal epileptiform discharges, diffuse nonepileptiform abnormalities, and for normal EEG recordings, and moderate beyond-chance agreement for the presence of focal nonepileptiform abnormalities. The performance of SCORE-AI was well within the variability present among human experts.

There is no other open-source or commercially available software package for comprehensive assessment of routine clinical EEGs. Several AI-based models have been developed for detection of epileptiform activity on EEG. However, this aspect is only a fragment of the complete comprehensive EEG assessment. The other major limitation of the previously published models is the high number of false detections (0.73 per minute) precluding their clinical implementation. A recent study reported that the fully automated application of 3 previously published AI models had specificity (3%-63%) that is too low for clinical application.

Human expert interaction via a semiautomated approach was needed to achieve clinical-level performance when using the previously published AI models. The benchmarking in our study confirms this, and shows that as opposed to previously published spike detectors, SCORE-AI reaches high specificity (90%) similar to human expert performance. In that data set, SCORE-AI had similar accuracy to the human raters, and significantly higher accuracy than the 3 previously published AI models. The important improvement in SCORE-AI compared with previous AI models is that our fully automated model achieves high specificity similar to human experts. We believe that the other AI models would probably improve their performance if the current limitations were addressed.

Table 4. Comparison of Fully Automated Identification of Epileptiform Discharges Between SCORE-AI and encevis on the Same 100 EEGs Used in the Multirater Test Set

<table>
<thead>
<tr>
<th>Algorithm</th>
<th>Fully automated identification of EEG recordings with epileptiform abnormalities, % (95% CI)</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Negative predictive value</th>
<th>Positive predictive value</th>
<th>Accuracy</th>
</tr>
</thead>
<tbody>
<tr>
<td>encevis a</td>
<td>96.68 (88.89-100.00)</td>
<td>27.14 (17.19-37.88)</td>
<td>95.03 (83.33-100.00)</td>
<td>36.29 (25.93-46.99)</td>
<td>48.03 (38.00-58.00)</td>
<td></td>
</tr>
<tr>
<td>SCORE-AI b</td>
<td>89.94 (77.78-100.00)</td>
<td>87.13 (78.79-94.29)</td>
<td>95.28 (89.39-100.00)</td>
<td>74.98 (60.00-88.57)</td>
<td>87.97 (81.00-94.00)</td>
<td></td>
</tr>
<tr>
<td>Difference (P&lt;.001)</td>
<td>&lt;.001</td>
<td>&lt;.001</td>
<td>.49</td>
<td>&lt;.001</td>
<td>&lt;.001</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: EEG, electroencephalography; SCORE-AI, Standardized Computer-based Organized Reporting of EEG—Artificial Intelligence.

a For encevis, the detection of one or more spikes was considered as epileptiform classification of the EEG.

b For SCORE-AI, either epileptiform-focal and/or epileptiform-generalized was considered as an epileptiform classification of the EEG.
A limitation of the current version of SCORE-AI is that it was implemented with some limitations. The expert-level performance of SCORE-AI warrants its application in remote and underserved areas. Its ability of the model in clinical practices because it does not require specialized hardware and it can also be converted into other computer-based interfaces.

**Limitations**

A limitation of the current version of SCORE-AI is that it was developed and validated on routine EEGs excluding neonates and critically ill patients. Nevertheless, routine EEGs represent the largest volume of EEG recordings performed for clinical purposes and is one of the most important missing clinical tests in underserved areas. Another important limitation is that the model was trained to find biomarkers visually identified by human experts. Training the model to predict diagnosis or therapeutic response can potentially circumvent this limitation, and this will be addressed in future studies. Using interpretable or explainable AI, the plan is to identify features used by the model to make the process transparent.

**Conclusions**

In this diagnostic accuracy study, our convolutional neural network model, SCORE-AI, achieved expert-level performance in reading routine clinical EEGs. Its application may help to provide useful clinical information in remote and underserved areas where expertise in EEG interpretation is minimal or unavailable. Importantly, it may also help reduce the potential for EEG misinterpretation and subsequent mistreatment, improve interrater agreement to optimize routine interpretation by neurologists, and increase efficiency by decompressing excessive workloads for human experts interpreting high volumes of EEGs.

**ARTICLE INFORMATION**

Accepted for Publication: March 23, 2023.
Published Online: June 20, 2023.

Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2023 Tveit J et al. JAMA Neurology.

Author Affiliations: Holberg EEG, Bergen, Norway (Tveit, Aurlien); Department of Clinical Neurophysiology, Haukeland University Hospital, Bergen, Norway (Aurlien); Tri-institutional Center for Translational Research in Neuroimaging and Data Science (TriENDS), Georgia State University, Georgia Institute of Technology, Emory University, Atlanta (Plis, Calhoun); Department of Neurology, Mayo Clinic, Jacksonville, Florida (Tatum); Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts (Schorer); Department of Neurology and Clinical Neurophysiology, St Olavs Hospital, Trondheim University Hospital, Norway (Arntsen); Department of Clinical Neurophysiology, Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, the Netherlands (Coa); Department of Neurology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Fahoum); Department of Neurology and Pediatrics, Stanford University Lucile Packard Children’s Hospital, Palo Alto, California (Gallentine); Department of Clinical Neurophysiology, Danish Epilepsy Centre, Dianaland, Denmark (Gardella, Beniczky); Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark (Gardella); Division of Neurology, The Hospital for Sick Children, Toronto, Canada (Hahn); Department of Paediatrics, University of Toronto, Toronto, Canada (Hahn); Department of Neurology, Duke University Medical Center, Durham, North Carolina (Husain); Neurodiagnostic Center, Veterans Affairs Medical Center, Durham, North Carolina (Husain); Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania (Kessler); Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania (Kessler); Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (Kessler); Department of Clinical Neurophysiology, Aarhus University Hospital, Aarhus, Denmark (Kural, Tankisi, Beniczky); Department of Clinical Medicine, Aarhus University, Aarhus, Denmark (Kural, Tankisi, Beniczky); Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts (Nascimento); Department of Neurology, Oslo University Hospital, Norway (Ulvin); Division of Neurology, Department of Medicine, Krembil Brain Institute, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, Canada (Wennberg).

Author Contributions: Drs Tveit and Aurlien had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analyses. Drs Tveit, Aurlien, and Beniczky contributed equally to this work. Concept and design: Tveit, Aurlien, Plis, Calhoun, Beniczky. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Tveit, Aurlien, Beniczky. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Tveit. Administrative, technical, or material support: Tveit, Aurlien, Beniczky. Supervision: Tveit, Aurlien, Beniczky. Conflict of Interest Disclosures: Dr Tveit reported being Senior Business Intelligence Developer in Holberg EEG; Holberg EEG received grants from Skattefunn R&D, a tax incentive government program; Natus Medical was a minority shareholder in Holberg EEG during the conduct of the study. Dr Aurlien reported being Chief Medical Officer and minority shareholder in Holberg EEG; Holberg EEG received grants from Skattefunn R&D, a tax incentive government program; Natus Medical was a minority shareholder in Holberg EEG during the conduct of the study. Dr Plis reported receiving consulting fees from Holberg EEG during the conduct of the study. Dr Gallentine reported receiving personal fees from Holberg EEG during the conduct of the study. Dr Hahn reported receiving personal fees from Holberg EEG during the conduct of the study and grants and personal fees from Takeda and UCB outside the submitted work. Dr Husain reported receiving personal fees from UCB, Jazz Pharma, Merck, Eisai, Marinus Pharmaceuticals, Pipeline Therapeutics, Neurelis, Springer Publishing, Demos Medical Publishing, and Wolters Kluwer outside the submitted work. Dr Ulvin reported that Oslo University Hospital was compensated by Holberg EEG during the conduct of the study. Dr Beniczky reported receiving personal fees from Natus Medical, UNEEG Medical, Eisai, and UCB outside the submitted work. No other disclosures were reported.

Funding/Support: The infrastructure needed for this study was funded by Holberg EEG. No other funding was received toward this work.

Role of the Funder/Sponsor: Holberg EEG had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See Supplement 2.
Additional Contributions: Thanks to Glenn Ba at Haukeland University Hospital, Norway; Rune Dybdahl at Filadelfia Epilepsy Hospital, Denmark; and Bistein Johnsen at Sykehuspartner HF, Norway, for assistance with anonymizing and downloading the EEGs used in the training and test datasets, and to Kristian Bernhard Nilsen for organizing this work at Oslo University Hospital. Thanks to the Holberg EEG team, especially Øyvind Gulbrandsen, Karsten Teige, Michelle Campbell, Abd Syed, Azhur Ahmed Syed, and Prasanna Venkatesh Rangadur for organizational and technical assistance, and to Christher Hannetveit, Katerina Georgopoulou, Humayan Khan Pathan, and Mikael Tureq for integrating the trained model into the Natus EEG system. Thanks to the physicians and technologists at Haukeland University Hospital, Norway; Filadelfia Epilepsy Hospital, Denmark, and Oslo University Hospital, Norway for scoring the EEGs used in the training and test datasets. No compensation was received apart from normal salary.

REFERENCES


